Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 5/20 | 0.38 |
| ▸ | TYK2 | P29597 | 5/20 | 0.38 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | USP7 | Q93009 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850537 | 0.80 | CDK2 (0.43) | CDK2CCNA1FLT3IDO1NOS1 | |
| SCHEMBL20850529 | 0.79 | NOS1 (0.50) | CDK2CCNA1FLT3IDO1NOS1 | |
| SCHEMBL14995563 | 0.79 | NOS1 (0.50) | CDK2CCNA1FLT3IDO1NOS1 | |
| SCHEMBL21891669 | 0.79 | CDK2 (0.42) | CDK2CCNA1FLT3IDO1NOS1 | |
| SCHEMBL19304040 | 0.76 | BRD4 (0.44) | CDK2CCNA1FLT3IDO1NOS1 | |
| SCHEMBL21217948 | 0.76 | TRPA1 (0.39) | CDK2CCNA1FLT3IDO1NOS1 | |
| SCHEMBL5412894 | 0.76 | SMN1; SMN2 (0.38) | CDK2CCNA1IDO1CCNA2NOS1 | |
| SCHEMBL5404343 | 0.76 | FGFR1 (0.44) | CDK2CCNA1IDO1CCNA2NOS1 | |
| SCHEMBL21196087 | 0.75 | TRPA1 (0.41) | CDK2CCNA1FLT3IDO1CCNA2 | |
| SCHEMBL21437262 | 0.75 | NOS1 (0.44) | CDK2CCNA1IDO1CCNA2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | CDK2 443/4885CCNA1 750/4885FLT3 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.